A Comparison of CPAP With and Without Humidification: A Pilot Study
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02423681 |
Recruitment Status :
Completed
First Posted : April 22, 2015
Last Update Posted : February 15, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Obstructive Sleep Apnea | Device: ThermoSmart Device: Without ThermoSmart | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 20 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Health Services Research |
Official Title: | Evaluation of Overall Therapy Cost Comparing First Intention and Second Intention Heated Humidification for CPAP: A Pilot Study. |
Actual Study Start Date : | June 2015 |
Actual Primary Completion Date : | October 2016 |
Actual Study Completion Date : | October 2016 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Heated humidification as first intention (HH1st)
Subjects receive heated humidification as first intention with ThermoSmart
|
Device: ThermoSmart
Heated humidification as first intention (HH1st) with ThermoSmart |
Placebo Comparator: Non-heated humidification
Subjects will receive no humidification. However they can be switched to the humidification group if patients complains of nasal dryness, congestion, nose bleed or if they had significant leak that cannot be resolved by two changes of mask.
|
Device: Without ThermoSmart
ThermoSmart is switched off |
- Overall cost of equipment [ Time Frame: 6 months ](cost of equipment required for CPAP therapy, including CPAP device and mask, and all related consumables
- Number and type of additional interventions [ Time Frame: 6 months ]The number and type of additional interventions (masks, nasal steroids) and the associated cost
- Duration of appointments [ Time Frame: 6 months ]Time spent with/on each patient (i.e preparation and follow-up time as well as appointment time)
- Number of unplanned follow-ups [ Time Frame: 6 months ]number of unplanned follow-ups
- Adherence to therapy [ Time Frame: 6 months ]Compliance data from the device
- Therapy Acceptance [ Time Frame: 6 months ]Number of withdrawals and drop out from the therapy
- Apnea Hypopnea Index (AHI) [ Time Frame: 6 months ]AHI to measure the treatment efficacy
- Leak [ Time Frame: 6 months ]Total system leak from the device
- Side effects and symptoms reported [ Time Frame: 6 months ]Any side effects and symptoms reported with the therapy
- Self-reported satisfaction [ Time Frame: 6 months ]Self-reported satisfaction via treatment questionnaires
- Patient sleeping environment temperature and humidity [ Time Frame: 6 months ]The temperature and humidity of the patient's environment as measured by a humidity logger

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Older than 18 years of age
- Diagnosed with OSA (obstructive sleep apnea) and eligible for CPAP treatment under local requirements (NICE guidelines: AHI (apnea hypopnea index) ≥ 15, or AHI > 5 with significant daytime sleepiness)
- Naïve to CPAP therapy, i.e. have not been prescribed, or used CPAP in the last 5 years.
- Fluent in spoken and written English
Exclusion Criteria:
- Significant uncontrolled cardiac disease, as per the principal investigator's discretion
- Co-existing lung disease, as per the principal investigator's discretion
- Co-existing sleep disorder, such a predominant central sleep apnoea
- Pregnancy
- Participants that are unable or unwilling to give informed consent.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02423681
United Kingdom | |
Lung Function and Sleep Unit, St George's Hospital | |
London, United Kingdom |
Principal Investigator: | Sara Parsons, Chief Clinical Physiologist | Lung Function and Sleep Unit, St George's Hospital |
Responsible Party: | Fisher and Paykel Healthcare |
ClinicalTrials.gov Identifier: | NCT02423681 |
Other Study ID Numbers: |
CIA-101 |
First Posted: | April 22, 2015 Key Record Dates |
Last Update Posted: | February 15, 2017 |
Last Verified: | February 2017 |
Sleep Apnea, Obstructive Sleep Apnea Syndromes Apnea Respiration Disorders Respiratory Tract Diseases |
Sleep Disorders, Intrinsic Dyssomnias Sleep Wake Disorders Nervous System Diseases |